Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/MDMA/Tobacco/Nicotine Use Disorder (TUD)

MDMA for Tobacco/Nicotine Use Disorder (TUD)

6 papers and 0 clinical trials exploring mdma as a treatment for tobacco/nicotine use disorder (tud).

Compoundempathogen

MDMA

MDMA is a synthetic empathogen that enhances monoamine release, producing prosocial and anxiolytic effects without frank hallucinosis. Two Phase III trials demonstrated significant PTSD symptom reductions, though FDA review raised concerns about blinding, durability, and safety characterisation.

Full MDMA profile
Indication1.3 billion smokers worldwide.

Tobacco/Nicotine Use Disorder (TUD)

Tobacco Use Disorder (TUD) presents significant challenges for public health, and emerging research indicates that psychedelic compounds may offer novel therapeutic avenues for treatment. Initial studies highlight the potential of psychedelics like ayahuasca and ibogaine in reducing tobacco dependence.

Full Tobacco/Nicotine Use Disorder (TUD) profile

Academic Research

6 papers
Open Accessmeta

The Acute Effects of Psychoactive Drugs on Emotional Episodic Memory Encoding, Consolidation, and Retrieval

This review shows that acute psychoactive drugs differentially affect emotional episodic memory depending on timing: drugs given before encoding can selectively impair (GABAA sedatives, THC, ketamine), enhance (dopaminergic/noradrenergic stimulants), or produce mixed effects (MDMA) on emotional versus neutral memories. GABAA sedatives administered immediately post‑encoding preferentially enhance consolidation of emotional memories (with specificity declining as retrieval is delayed), and intoxication at retrieval (THC, dextroamphetamine, MDMA) increases false memories—especially for positive content—while the authors outline neural mechanisms, methodological considerations and implications for recreational and medical use.

Published
June 2, 2022
Journal
Psyarxiv
Authors
Doss, M. K., de Wit, H., Gallo, D. A.
Paywallmeta

Human behavioral pharmacology of psychedelics

This commentary (2021) provides an overview of the human behavioural pharmacology of the classic psychedelic; psilocybin, LSD and DMT. Special considerations when conducting human research with psychedelics are discussed as well as the subjective, physiological, and clinical effects of these substances.

Published
January 1, 2022
Journal
Advances in Pharmacology
Authors
Strickland, J. C., Johnson, M. W.
Open Accessmeta

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects

This pooled analysis (n=139) of double-blind, placebo-controlled studies reviews the role of genetic polymorphisms in CYP2C19, CYP2B6, and CYP1A2 in the metabolism of MDMA in humans. The research shows affirmed that these enzymes play a significant role in the metabolism of MDMA to MDA in humans and that genetic polymorphism in CYP2C19 could moderate MDMA's cardiovascular toxicity.

Published
March 1, 2017
Journal
European Neuropsychopharmacology
Authors
Vizeli, P., Schmid, Y., Prestin, K., Meyer Zu Schwabedissen, H. E., Liechti, M. E.
Paywallindividual

Predicting the Abuse Liability of Entactogen-Class, New and Emerging Psychoactive Substances via Preclinical Models of Drug Self-administration

This book chapter (2016) investigates animal models of drug abuse potential (addiction) of psychedelics. It finds that MDMA is self-administered (by mice) but less frequently than (meth)amphetamine or two novel psychedelic compounds (4MMC, methylone).

Published
December 2, 2016
Journal
Neuropharmacology
Authors
Aarde, S. M., Taffe, M. A.
Open Accessmeta

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

This commentary article (2016) by Mithoefer, Grob, and Brewerton gives an overview of recent research into psilocybin and MDMA.

Published
April 5, 2016
Journal
Lancet Psychiatry
Authors
Grob, C. S., Mithoefer, M. C., Brewerton, T. D.
Open Accessmeta

Psychedelics

This paper is the most comprehensive review of psychedelics research up to 2016 by the eminent David E. Nichols.

Published
April 1, 2016
Journal
Pharmacological Reviews
Authors
Nichols, D. E.

Clinical Trials

0 trials

No clinical trials have been tagged with both MDMA and Tobacco/Nicotine Use Disorder (TUD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all MDMA papers Search all Tobacco/Nicotine Use Disorder (TUD) trials Full MDMA profile Full Tobacco/Nicotine Use Disorder (TUD) profile